Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 9OTHER 7NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 31Multiple Myeloma 7Lymphoma, Non-Hodgkin 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms, Plasma Cell 6Monoclonal Gammopathy of Undetermined Significance 6Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia 6Hodgkin Disease 6Burkitt Lymphoma 6Waldenstrom Macroglobulinemia 5Thrombocythemia, Essential 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Polycythemia Vera 5Myeloproliferative Disorders 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myeloid, Chronic-Phase 5Leukemia, Myeloid, Acute 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Hairy Cell 5Immunoblastic Lymphadenopathy 5Uterine Cervical Neoplasms 4Uterine Cervical Dysplasia 4Primary Myelofibrosis 4

Interventions

tipifarnib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Advanced Malignant Neoplasm × Other neoplasm × Clear all
NCT00244972 2017-04-27

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
74 enrolled
Other neoplasm

Advanced Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡